175 related articles for article (PubMed ID: 30098331)
1. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
[TBL] [Abstract][Full Text] [Related]
2. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
[TBL] [Abstract][Full Text] [Related]
3. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C regulates ErbB3 turnover.
Dietrich M; Malik MS; Skeie M; Bertelsen V; Stang E
Exp Cell Res; 2019 Sep; 382(2):111473. PubMed ID: 31233741
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
6. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
[TBL] [Abstract][Full Text] [Related]
7. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
[TBL] [Abstract][Full Text] [Related]
8. Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes.
Vuong TT; Berger C; Bertelsen V; Rødland MS; Stang E; Madshus IH
Exp Cell Res; 2013 Feb; 319(3):32-45. PubMed ID: 23127513
[TBL] [Abstract][Full Text] [Related]
9. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Barr DJ; Ostermeyer-Fay AG; Matundan RA; Brown DA
J Cell Sci; 2008 Oct; 121(Pt 19):3155-66. PubMed ID: 18765569
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 degradation mediated by the co-chaperone protein CHIP.
Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H
J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167
[TBL] [Abstract][Full Text] [Related]
11. A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair.
Bruns AF; Yuldasheva N; Latham AM; Bao L; Pellet-Many C; Frankel P; Stephen SL; Howell GJ; Wheatcroft SB; Kearney MT; Zachary IC; Ponnambalam S
PLoS One; 2012; 7(11):e48539. PubMed ID: 23139789
[TBL] [Abstract][Full Text] [Related]
12. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
14. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
Marx C; Held JM; Gibson BW; Benz CC
Cancer Res; 2010 May; 70(9):3709-17. PubMed ID: 20406983
[TBL] [Abstract][Full Text] [Related]
15. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
[TBL] [Abstract][Full Text] [Related]
16. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.
Xu W; Mimnaugh EG; Kim JS; Trepel JB; Neckers LM
Cell Stress Chaperones; 2002 Jan; 7(1):91-6. PubMed ID: 11892991
[TBL] [Abstract][Full Text] [Related]
17. Sustained activation of protein kinase C downregulates nuclear factor-kappaB signaling by dissociation of IKK-gamma and Hsp90 complex in human colonic epithelial cells.
Park KA; Byun HS; Won M; Yang KJ; Shin S; Piao L; Kim JM; Yoon WH; Junn E; Park J; Seok JH; Hur GM
Carcinogenesis; 2007 Jan; 28(1):71-80. PubMed ID: 16774932
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
Suzuki T; Fujii A; Ochi H; Nakamura H
J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
[TBL] [Abstract][Full Text] [Related]
20. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
